121 related articles for article (PubMed ID: 29638149)
41. Emerging antibodies for the treatment of pancreatic cancer.
Andrikou K; Peterle C; Pipitone S; Salati M; Cascinu S
Expert Opin Emerg Drugs; 2017 Mar; 22(1):39-51. PubMed ID: 28253833
[TBL] [Abstract][Full Text] [Related]
42. Translational research in pancreatic cancer. Highlights from the "2010 ASCO Gastrointestinal Cancers Symposium". Orlando, FL, USA. January 22-24, 2010.
Strimpakos AS; Syrigos KN; Saif MW
JOP; 2010 Mar; 11(2):124-7. PubMed ID: 20208318
[TBL] [Abstract][Full Text] [Related]
43. Time to the initiation of adjuvant chemotherapy does not impact survival in patients with resected pancreatic cancer.
Mirkin KA; Greenleaf EK; Hollenbeak CS; Wong J
Cancer; 2016 Oct; 122(19):2979-87. PubMed ID: 27328270
[TBL] [Abstract][Full Text] [Related]
44. Novel dual Src/Abl inhibitors for hematologic and solid malignancies.
Schenone S; Brullo C; Musumeci F; Botta M
Expert Opin Investig Drugs; 2010 Aug; 19(8):931-45. PubMed ID: 20557276
[TBL] [Abstract][Full Text] [Related]
45. The role of pancreatic and duodenal homeobox 1 as a therapeutic target in pancreatic cancer.
Fendrich V; Lauth M
Expert Opin Ther Targets; 2014 Nov; 18(11):1277-83. PubMed ID: 25078025
[TBL] [Abstract][Full Text] [Related]
46. Masitinib demonstrates anti-proliferative and pro-apoptotic activity in primary and metastatic feline injection-site sarcoma cells.
Lawrence J; Saba C; Gogal R; Lamberth O; Vandenplas ML; Hurley DJ; Dubreuil P; Hermine O; Dobbin K; Turek M
Vet Comp Oncol; 2012 Jun; 10(2):143-54. PubMed ID: 22236016
[TBL] [Abstract][Full Text] [Related]
47. Recent advances in the management of pancreatic adenocarcinoma.
Karakas Y; Lacin S; Yalcin S
Expert Rev Anticancer Ther; 2018 Jan; 18(1):51-62. PubMed ID: 29125367
[TBL] [Abstract][Full Text] [Related]
48. Therapeutic Approaches for Metastatic Pancreatic Adenocarcinoma.
Rubinson DA; Wolpin BM
Hematol Oncol Clin North Am; 2015 Aug; 29(4):761-76. PubMed ID: 26226909
[TBL] [Abstract][Full Text] [Related]
49. Targeting the Akt/PI3K Signaling Pathway as a Potential Therapeutic Strategy for the Treatment of Pancreatic Cancer.
Ebrahimi S; Hosseini M; Shahidsales S; Maftouh M; Ferns GA; Ghayour-Mobarhan M; Hassanian SM; Avan A
Curr Med Chem; 2017; 24(13):1321-1331. PubMed ID: 28176634
[TBL] [Abstract][Full Text] [Related]
50. Advanced stage pancreatic cancer: novel therapeutic options.
Saif MW
Expert Rev Clin Pharmacol; 2014 Jul; 7(4):487-98. PubMed ID: 24939470
[TBL] [Abstract][Full Text] [Related]
51. In vitro effects of the tyrosine kinase inhibitor, masitinib mesylate, on canine hemangiosarcoma cell lines.
Lyles SE; Milner RJ; Kow K; Salute ME
Vet Comp Oncol; 2012 Sep; 10(3):223-35. PubMed ID: 22594682
[TBL] [Abstract][Full Text] [Related]
52. Phase 1 dose-escalation study of oral tyrosine kinase inhibitor masitinib in advanced and/or metastatic solid cancers.
Soria JC; Massard C; Magné N; Bader T; Mansfield CD; Blay JY; Bui BN; Moussy A; Hermine O; Armand JP
Eur J Cancer; 2009 Sep; 45(13):2333-41. PubMed ID: 19541476
[TBL] [Abstract][Full Text] [Related]
53. Depression in patients with mastocytosis: prevalence, features and effects of masitinib therapy.
Moura DS; Sultan S; Georgin-Lavialle S; Pillet N; Montestruc F; Gineste P; Barete S; Damaj G; Moussy A; Lortholary O; Hermine O
PLoS One; 2011; 6(10):e26375. PubMed ID: 22031830
[TBL] [Abstract][Full Text] [Related]
54. The development of multi-kinase inhibitors as pancreatic cancer therapeutics.
Dent P; Poklepovic A; Booth L; Hancock JF
Anticancer Drugs; 2021 Sep; 32(8):779-785. PubMed ID: 34397447
[TBL] [Abstract][Full Text] [Related]
55. Pharmacokinetics of masitinib in cats.
Bellamy F; Bader T; Moussy A; Hermine O
Vet Res Commun; 2009 Dec; 33(8):831-7. PubMed ID: 19533403
[TBL] [Abstract][Full Text] [Related]
56. Effects of Tyrosine Kinase Inhibitor-masitinib Mesylate on Canine Mammary Tumour Cell Lines.
Ustun-Alkan F; Bakırel T; Üstüner O; Anlas C; Cinar S; Yıldırım F; Gürel A
J Vet Res; 2021 Sep; 65(3):351-359. PubMed ID: 34917849
[TBL] [Abstract][Full Text] [Related]
57. Masitinib as a neuroprotective agent: a scoping review of preclinical and clinical evidence.
Hamad AA; Amer BE; Hawas Y; Mabrouk MA; Meshref M
Neurol Sci; 2024 May; 45(5):1861-1873. PubMed ID: 38105307
[TBL] [Abstract][Full Text] [Related]
58. Pancreatic cancer from bench to bedside: molecular pathways and treatment options.
Kosmidis C; Sapalidis K; Kotidis E; Mixalopoulos N; Zarogoulidis P; Tsavlis D; Baka S; Man YG; Kanellos J
Ann Transl Med; 2016 May; 4(9):165. PubMed ID: 27275478
[TBL] [Abstract][Full Text] [Related]
59. Mechanism and Effect of Beta-Blockers on Pancreatic Adenocarcinoma: A Literature Review.
Upadhyaya VD; Douedi S; Garcia B; Gonzalez J; Udongwo N; Wei J; Nai Q; Asif A; Sen S
J Clin Med Res; 2020 Dec; 12(12):753-757. PubMed ID: 33447308
[TBL] [Abstract][Full Text] [Related]
60. Neoadjuvant Therapy is Essential for Resectable Pancreatic Cancer.
Xu JZ; Wang WQ; Zhang SR; Xu HX; Wu CT; Qi ZH; Gao HL; Li S; Ni QX; Yu XJ; Liu L
Curr Med Chem; 2019; 26(40):7196-7211. PubMed ID: 29651946
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
